Merck KGaA, Darmstadt, Germany to Present New Research Focused on Hard-to-Treat Cancers at ESMO 2016

DARMSTADT, Germany, Sept. 28, 2016 /CNW/ -

Not intended for UK-based media

ESMO Abstract #
Avelumab: 777PD, 7775PD, 1154P, 842TiP, 844TiP; Erbitux: 527P, 491P, 967P, 994P; Tepotinib: 1257P, 1287TiP, 1292TiP

  • Merck KGaA, Darmstadt, Germany, to feature new research from marketed and pipeline compounds
  • Preliminary results from combination study with avelumab in renal cell carcinoma, and updates on Phase II tepotinib program in
    non-small cell lung cancer, to be presented
  • Merck KGaA, Darmstadt, Germany, to announce 2016 Grant for Oncology Innovation winners coinciding with ESMO

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that new research from their marketed and pipeline compounds will be presented at this year's European Society for Medical Oncology (ESMO; October 7-11, 2016, Copenhagen, Denmark) annual meeting. Presentations will focus on hard-to-treat cancers, and include: study results for Erbitux® (cetuximab) in metastatic colorectal cancer (mCRC) and squamous cell carcinoma of the head and neck (SCCHN); preliminary study results in bladder cancer and renal cell carcinoma (RCC) for avelumab, which is being developed in collaboration with Pfizer; and updates on the Phase II program for tepotinib* in non-small cell lung cancer (NSCLC).

"The data being presented at ESMO reflect our commitment to making a meaningful difference in patients' lives, in particular those who are affected by hard-to-treat cancers," said Luciano Rossetti, Executive Vice President, Head of Global Research & Development at the biopharma business of Merck KGaA, Darmstadt, Germany. "We continue to focus on researching the full potential of Erbitux, as well as our ongoing pipeline development programs for avelumab and other early-stage oncology and immune-oncology compounds."

At ESMO, avelumab will be featured in four posters that add to the growing body of evidence of the potential of this investigational compound. These will include data updates in bladder cancer that confirm avelumab's potential in this hard-to-treat cancer; and preliminary results from a combination study with axitinib in RCC that support the rationale to evaluate the combination in a Phase III pivotal study. Tepotinib, a highly selective c-Met kinase inhibitor, will also be highlighted in three posters, with updates on the ongoing study program in c-Met-positive metastatic NSCLC.

Several studies, which will be presented at ESMO, once again reaffirm Erbitux as a standard-of-care therapy for mCRC patients with RAS wild-type tumors and patients with SCCHN.

Merck KGaA, Darmstadt, Germany, believes that to truly deliver the promise of innovation for patients, it is vital to support and encourage research from other endeavors. This is demonstrated through Merck KGaA, Darmstadt, Germany's Grant for Oncology Innovation (GOI) initiative, which awards researchers for their pioneering independent work in pushing the boundaries of creativity and science in order to deliver transformative innovation. The award ceremony will once again coincide with ESMO and takes place on Sunday, October 9, 2016.

*Tepotinib is the proposed nonproprietary name for the c-Met kinase inhibitor (also known as MSC2156119J).

Avelumab and tepotinib are under clinical investigation and have not been proven to be safe and effective. There is no guarantee any product will be approved in the sought-after indication by any health authority worldwide.

Notes to Editors

Accepted Merck KGaA, Darmstadt, Germany-supported abstracts are listed below. In addition, a number of investigator-sponsored studies have been accepted, including several related to Erbitux (not listed).

Title

Lead
Author

Abstract
#

Presentation

date/time

(CDT)

Session

Room/
Details







Erbitux












Impact of tumor
epidermal growth factor
receptor (EGFR) status
on the outcomes of
first-line FOLFOX-4
plus or minus cetuximab
in patients (pts) with
RAS-wild-type (wt)
metastatic colorectal
cancer (mCRC) in the
randomized phase 3
TAILOR trial

S Qin

527P

October 8

13:00-14:00

Poster Display

Session

Hall E







Impact of surgical

resection of liver

metastases on outcome

of patients with

metastatic colorectal

carcinoma (mCRC)

treated with a

cetuximab-based

first-line therapy -

Analysis of the

KRAS-wildtype exon 2

(KRAS-wt) subgroup of

the German

non-interventional

study ERBITAG

U Neumann

491P

October 8

13:00-14:00

Poster Display

Session

Hall E







Observational study of

the dose intensity

relative to cetuximab
in the first-line
treatment of recurrent
and/or metastatic
squamous cell carcinoma
of the head and neck:
data on the maintenance
and bi-weekly use
(DIRECT study)

J Guigay

967P

October 9

13:00-14:00

Poster Display

Session

Hall E







Cetuximab in

combination with

platinum-based
chemotherapy or
radiotherapy in
recurent and/or
metastatic SCCHN in a
non-selected patient
cohort (interim
analysis of the phase
IV SOCCER trial)

M Hecht

994P

October 9

13:00-14:00

Poster Display

Session

Hall E

 

Title

Lead
Author

Abstract
#

Presentation

date/time

(CDT)

Session

Room/
Details







Avelumab












Avelumab (MSB0010718C;

anti-PD-L1) in patients

with metastatic

urothelial carcinoma

progressed after

platinum-based therapy

or platinum ineligible

M Patel

777PD

October 9

16:30-17:30

Poster

Discussion

Session

Genitourinary

tumors, non-

prostate

Athens







Phase 1b dose-finding

study of avelumab

(anti-PD-L1) + axitinib

in treatment-naïve

patients with advanced

renal cell carcinoma

J Larkin

775PD

October 9

16:30-17:30

Poster

Discussion

Session

Genitourinary

tumors, non-

prostate

Athens







Evaluation of real

world treatment

outcomes in patients
with metastatic Merkel
cell carcinoma (MCC)
following second line
chemotherapy

J Becker

1154P

October 9

13:00-14:00

Poster Display

Session

Hall E







A multicenter,

international,

randomized, open-label
phase 3 trial of
avelumab + best
supportive care (BSC)
vs BSC alone as
maintenance therapy
after first-line
platinum-based
chemotherapy in
patients with advanced
urothelial cancer
(JAVELIN Bladder 100)

T Powles

842TiP

October 9

13:00-14:00

Poster Display

Session

Hall E







Phase 3 study of

avelumab in combination

with axitinib versus
sunitinib as first-line
treatment for patients
with advanced renal
cell carcinoma (aRCC)

R Motzer

844TiP

October 9

13:00-14:00

Poster Display

Session

Hall E

 

Title

Lead
Author

Abstract
#

Presentation

date/time

(CDT)

Session

Room/
Details







Tepotinib












Tepotinib plus

gefitinib in patients

with

c-Met-positive/EGFR-mutant

NSCLC: recommended

phase II dose (RP2D),

tolerability, and

efficacy

Y-L Wu

1257P

October 8

13:00-14:00

Poster Display

Session

Hall E







Design of a phase II

trial comparing

tepotinib + gefitinib
with cisplatin +
pemetrexed in EGFR
inhibitor-resistant,
c-Met+ NSCLC

Y-L Wu

1287TiP

October 8

13:00-14:00

Poster Display

Session

Hall E







A phase II trial

investigating the

highly selective c-Met
inhibitor tepotinib in
stage IIIB/IV lung
adenocarcinoma with MET
exon 14 alterations
after failure of at
least one prior therapy

P Paik

1292TiP

October 8

13:00-14:00

Poster Display

Session

Hall E

 

For further information and press materials please visit:http://www.emdgroup.com/emd/media/media_center_oncology.html

All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to http://www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

About Avelumab

Avelumab (also known as MSB0010718C) is an investigational, fully human antibody specific for a protein found on tumor cells called PD-L1, or programmed death ligand-1. Avelumab is thought to have a dual mechanism of action which may enable the immune system to find and attack cancer cells. By binding to PD-L1, avelumab is thought to prevent tumor cells from using PD-L1 for protection against white blood cells such as T-cells, exposing them to anti-tumor responses. Avelumab is also thought to help white blood cells such as natural killer (NK) cells find and attack tumors in a process known as ADCC, or antibody-dependent cell-mediated cytotoxicity. In November 2014, Merck KGaA, Darmstadt, Germany, and Pfizer announced a strategic alliance to co-develop and co-commercialize avelumab.

About Erbitux

Erbitux® is a highly active IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). As a monoclonal antibody, the mode of action of Erbitux is distinct from standard non-selective chemotherapy treatments in that it specifically targets and binds to the EGFR. This binding inhibits the activation of the receptor and the subsequent signal-transduction pathway, which results in reducing both the invasion of normal tissues by tumor cells and the spread of tumors to new sites. It is also believed to inhibit the ability of tumor cells to repair the damage caused by chemotherapy and radiotherapy and to inhibit the formation of new blood vessels inside tumors, which appears to lead to an overall suppression of tumor growth.

The most commonly reported side effect with Erbitux is an acne-like skin rash. In approximately 5% of patients, hypersensitivity reactions may occur during treatment with Erbitux; about half of these reactions are severe.

Erbitux has already obtained market authorization in over 90 countries world-wide for the treatment of colorectal cancer and for the treatment of squamous cell carcinoma of the head and neck (SCCHN). Merck KGaA, Darmstadt, Germany, licensed the right to market Erbitux outside the US and Canada from ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company, in 1998. Merck KGaA, Darmstadt, Germany, has an ongoing commitment to the advancement of oncology treatment and is currently investigating novel therapies in highly targeted areas.

About Tepotinib

Tepotinib (also known as MSC2156119J) is an investigational small-molecule inhibitor of the c-Met receptor tyrosine kinase capable of inhibiting both hepatocyte growth factor-dependent and -independent c-MET activation in low nanomolar concentrations. Alterations of the c-Met signaling pathway are found in various cancer types and correlate with aggressive tumor behavior and poor clinical prognosis. Tepotinib is currently under evaluation in Phase I/II trials.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck KGaA, Darmstadt, Germany, generated sales of € 12.85 billion in 66 countries.

Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the Merck KGaA, Darmstadt, Germany, name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

(Logo: http://photos.prnewswire.com/prnh/20160629/384917LOGO )

SOURCE Merck KGaA

For further information: Heike Schmiedt, +49-6151-72-7498


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890